Dr Reddys Laboratories (RDY) Net Income towards Common Stockholders (2009 - 2023)

Dr Reddys Laboratories' Net Income towards Common Stockholders history runs 15 years deep, the most recent figure standing at $178.0 million for Q2 2023.

• In Q2 2023, Net Income towards Common Stockholders changed N/A year-over-year to $178.0 million; the TTM figure through Mar 2026 stood at $178.0 million (down 48.7% YoY), while the FY2026 annual figure was $456.0 million, down 31.22% from the prior year.
• Net Income towards Common Stockholders for Q2 2023 stood at $178.0 million, up from $169.0 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $178.0 million in Q2 2023, with the low at -$108.0 million in Q3 2020.
• The 5-year median for Net Income towards Common Stockholders is $105.5 million (2019), against an average of $80.2 million.
• Peak annual rise in Net Income towards Common Stockholders reached 121.74% in 2019, while the deepest fall reached 214.29% in 2019.
• Dr Reddys Laboratories' Net Income towards Common Stockholders stood at -$80.0 million in 2019, then plunged by 35.0% to -$108.0 million in 2020, then surged by 224.07% to $134.0 million in 2021, then slipped by 12.69% to $117.0 million in 2022, then soared by 52.14% to $178.0 million in 2023.
• Business Quant data shows RDY's Net Income towards Common Stockholders at $178.0 million in Q2 2023, $169.0 million in Q1 2023, and $117.0 million in Q4 2022.